Real world use of biologic drug levels and anti-drug antibodies in patients with psoriasis – does therapeutic drug monitoring have a place in routine clinical practice?

Abstract

Background: Psoriasis is a chronic disorder with increasing new treatments targeting the T-helper cell (Th)-1/Th17 axis. There remains a subset of patients who experience a primary or secondary failure to biologic treatments.

Methods: We present ten patients with psoriasis who failed biologic therapy with measurement of serum drug levels and anti-drug antibody levels (ADAs) with review of the current literature. Our objective was to identify demographic factors, disease status, drug level and ADAs which might correlate with primary and secondary failure.

Results: There are a number of factors affecting drug levels in patients with psoriasis on biologics including the presence of ADAs, patient adherence to treatment regimes, pharmacogenetics and the pharmacokinetic properties of the drug following subcutaneous injection. Our results demonstrate that biologic failure is related to low serum drug levels subtherapeutic in 80% of our cohort. Primary failure may correlate with the presence of ADAs but not with serum drug levels. All patients were ANA negative and there remains considerable debate on the utility of routine ANA testing.

Conclusions: The role of therapeutic drug monitoring in dermatology remains uncertain and requires further study. We aim to promote debate in the dermatology community as to the utility of therapeutic drug monitoring in routine practice.

Keywords:

• Psoriasis
• biologic drugs
• anti-drug antibodies
• drug levels
• ANA
• biologic failure

Acknowledgements

The authors would like to acknowledge the contribution of biologic nurse specialists Eleanor Henderson and Lorraine Gribben in obtaining patient serum samples.

Disclosure statement

No potential conflict of interest was reported by the author(s).